

AD _____

Award Number: DAMD17-96-1-6095

TITLE: The Brcal Tumor - Suppressor Gene in a Mouse Model of
Breast Cancer

PRINCIPAL INVESTIGATOR: Timothy F. Lane, Ph.D.

CONTRACTING ORGANIZATION: University of California, Los Angeles
Los Angeles, California 90095-1406

REPORT DATE: October 1999

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20000829 013

-REPORT DOCUMENTATION PAGE-Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE October 1999	3. REPORT TYPE AND DATES COVERED Annual Summary (01 Oct 96 - 30 Sep 99)
----------------------------------	--------------------------------	--

4. TITLE AND SUBTITLE The Brca1 Tumor - Suppressor Gene in a Mouse Model of Breast Cancer	5. FUNDING NUMBERS DAMD17- 96-1-6095
--	---

6. AUTHOR(S) Timothy F. Lane, Ph.D.
--

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, Los Angeles Los Angeles, California 90095-1406 e-mail: tlane@mednet.ucla.edu	8. PERFORMING ORGANIZATION REPORT NUMBER
---	--

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSORING / MONITORING AGENCY REPORT NUMBER
---	--

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distributed unlimited	12b. DISTRIBUTION CODE
--	------------------------

13. ABSTRACT (Maximum 200 Words) BRCA1 is a tumor-suppressor locus on chromosome 17q21. Familial inheritance of a defective copy places a lifetime risk of breast cancer at 80%. Most of these tumors arise before the age of 50. In addition, there is an elevated risk of ovarian and testicular tumors. The mechanism of transformation is not known. In an effort to better understand the actions of this gene, I have cloned the mouse <i>Brca1</i> gene. The present proposal aims to characterize the effect of over-expression and deletion of <i>Brca1</i> in mice, and by understanding the nature of the interactions between <i>Brca1</i> and other oncogenes. The completion of these aims will provide: (1) a mouse model of <i>Brca1</i> deficiency, (2) an enhanced understanding of <i>Brca1</i> function in the regulation of mammary epithelial cell growth and differentiation, and (3) reveal important interactions between <i>Brca1</i> and other potent transforming agents in the breast, in particular with <i>c-myc</i> , and loss of p53.

14. SUBJECT TERMS Breast Cancer	15. NUMBER OF PAGES 8
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited
---	--	---	---

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

NA Where copyrighted material is quoted, permission has been obtained to use such material.

NA Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

NA For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

NA In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NA In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

NA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.


PI - Signature

Date

1999 Annual Report for Grant Number DAMD17-96-1-6095

Title: The Brcal Tumor - Suppressor Gene in a Mouse Model of Breast Cancer

TABLE OF CONTENTS:

Page #

1	Table of contents
2	Introduction
2	Body
3	Conclusions
4	References

INTRODUCTION:

In our original application, we proposed to investigate the following specific aims:

1. Characterize of the effects of *Brcal* expression on the proliferation and differentiation of breast cancer cells of known genotype.
2. Establish mice that lack functional *Brcal* by targeted disruption.
3. Genetic complementation of *Brcal* deficient mice with strains that express oncogenes known to contribute to the development of breast cancer.

As reported in the previous two years we have made significant progress on all three aims. In particular, we have studied the effect of overexpressing BRCA1 in mouse mammary epithelial cells and have studied the subcellular localization of the murine *Brcal* gene product (Aim 1). These experiments were completed and summarized in 1997 annual report.

As reported in 1998, we created a line of transgenic mice that overexpress human BRCA1 (MBR) (aim 1) and have created a second group of mice that overexpress an antisense construct of mouse *Brcal*(BAS) (aim 1). We have created a line of mice that carry an inactivated *Brcal* locus (BrKO) (aim 2) and have crossed the BrKO mice with mice predisposed to cancer, including (p53^{+/+}, p21^{+/+}, and MMTV-myc) (Aim 3). In the course of these experiments, we experienced several technical difficulties which hindered our progress. In particular, BrKO mice do not develop cancer and mating with cancer prone p53^{+/+}, p21^{+/+}, or MMTV-myc strains did not appear to accelerate or contribute to tumor progression of these strains.

In this final report we will summarize our results with BAS (MMTV-*Brcal* antisense) mice which were substituted for BrKO mice in Aim 3. We have crossed the BAS mice into p53^{+/+} and MMTV-c-neu backgrounds. As described below, we find that BAS mice are tumor prone and that tumor incidence is accelerated in p53null backgrounds. Interestingly, tumor progression was unchanged, or even delayed in BASx MMTV-c-neu mice. These results are discussed in the context of information on the incidence of p53 mutations and erbB2 amplifications observed in human BRCA1 associated breast cancers.

BODY:

Analysis of tumor formation in *Brcal* knock-out (BrKO) mice:

As described in the 1997 and 1998 progress report, BrKO mice were established on the 129^{SvEv} genetic background and have been monitored since 1996. In all respects, the phenotype of these mice appears similar to that described by other groups who have knocked out the *Brcal* gene (6, 8, 11, 12). Since that time we have mated the line with FVB-N and backcrossed into FVB to create a syngeneic strain on the FVB genetic background. Homozygous BrKO^{FVB} mice (BrKO^{FVB}/BrKO^{FVB}) display embryonic lethality at day 8-9 of development and thus are not useful for analysis of tumor progression. We also fail to identify tumors in heterozygous animals (BrKO^{FVB+/+}), a result consistent with other groups. To date, we have analyzed over 400 mice that reached 12 mo of age or greater.

Generation of Transgenic mice expressing MMTV-*Brcal* Antisense (TgN-MMTV-BAS) and MMTV-BRCA1:

- A) To overcome the long latency in tumor progression in BrKO^{+/+}, we generated several lines of transgenic mice expression a *Brcal* antisense (TgN-MMTV-BAS) construct targeted to the mammary gland (Table #1). The justification and strategy for creating these mice was described in the 1997 progress report.

- B) We also tried to generate several dominant overexpresser lines using human BRCA1 cDNA's linked to various ubiquitous (CMV, b-actin) or tissue specific (MMTV) promoters but never recovered successfully integrated founder animals. One founder that carried an MMTV-BRCA1 cDNA was recovered. Later analysis of tissues from offspring of this animal showed no expression and the line was discontinued. We concluded that inappropriate expression of BRCA1 was detrimental to murine development and have initiated a second line of research to evaluate BRCA1 promoter elements that can be used to direct the expression of transgenes.

The new lines that were created are described in Table 1.

Table 1 Transgenic mice (new lines)

<u>Construct/transgene</u>	<u>Name</u>	<u># of lines</u> ¹	<u>tumor formation</u>	<u>Transgene expression</u>
MMTV-Brcal antisense	BAS	8	yes (3/8 lines)	yes (3/3 tested)
MMTV-BRCA1	MBR	1	no	no
beta-actin-BRCA1		0	N.A. ⁴	N.A
CMV-BRCA1		0	N.A.	N.A

¹Number of lines represents the number of founders that transmitted transgenic DNA to offspring.

⁴Not applicable, this construct appears to result in embryonic lethality.

TgN-MMTV-BAS mice (BRCA1 antisense) have been in the lab for 3.5 years. Upon dexamethasone treatment, 3 week old BAS females show evidence of mammary hyperplasia with increased numbers of branch points in the mammary tree (see Figures 1 and 2 from the last annual report). Non-treated (dexamethasone free) females develop mammary adenocarcinomas with long latency (6-12 months (Figure 2). The incidence is low (4/20 mice > 8mo of age). We have now mated these mice into a p53 null background. Bigenic BAS/p53 colony develop mammary adenocarcinomas much more rapidly (3-4 months) and the tumors have a characteristic increase in vascularity. The incidence of mammary tumors is significantly increased over p53 alone indicating that the BAS transgene collaborates with loss of p53 in tumor formation. The strategy of targeting Brcal antisense (BAS) appears to be a more effective means of eliminating Brcal expression than waiting for allelic loss at the endogenous Brcal locus in BrKO mice. It therefore is a very promising alternative for studying BRCA1 induced tumors.

We have also generated a number of BASxMMTV-c-neu mice. Interestingly, in over 20 bigenic animals observed to date, tumors develop with longer latency than do MMTV-c-neu monogenic mice. Also, do MMTV-c-neu monogenic mice usually develop multiple tumor foci by 4-6 months whereas the bigenic mice usually only present with a single tumor mass. We are pursuing this result as it might help explain the lack of erbB2 amplifications reported in human BRCA1 mediated breast cancers.

We have established cell lines from the BAS mice in the hopes of demonstrating reduced Brcal protein expression. Unfortunately, commercially available anti-mouse Brcal protein antibodies (Santa Cruz) fail to work well in our hands. We have developed an very sensitive RNase protection assay which we hope will allow us to prove the mechanism.

Conclusions:

At the end of year 3, we have made progress on all 3 Aims. We have shown that mouse Brcal is a nuclear protein that blocks cell proliferation when overexpressed. We have also shown that Brcal is an essential gene. Loss of the gene in BrKO mice results in early

embryonic lethality. Heterozygous BrKO animals are healthy and do not appear to show increased susceptibility to breast cancers, or to any other disease states. While the lack of disease in BrKO mice has been disappointing, the Brca1 antisense (BAS) approach appears to be working. Specifically, we appear to be able to reduce Brca1 protein levels to the point where we can observe increased proliferation (hyperplasias) without inducing cellular lethality. We will continue characterizing these mice. To date 3 out of 8 BAS lines have developed at least one mammary tumor and we are particularly focused on line G which appears particularly cancer prone.

REFERENCES:

1. Chen, Y., C. F. Chen, D. J. Riley, D. C. Allred, P. L. Chen, D. Von Hoff, C. K. Osborne, and W. H. Lee. 1995. Aberrant subcellular localization of BRCA1 in breast cancer. *Science*. 270:789-791.
2. Chen, Y., A. A. Farmer, C. F. Chen, D. C. Jones, P. L. Chen, and W. H. Lee. 1996. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. *Cancer Res*. 56:3168-3172.
3. Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21^{CIP1}/WAF1 undergo normal development, but are defective in G1 checkpoint control. *Cell*. 82:675-684.
4. Donehower, L. A., L. Godley, C. Aldaz, R. Pyle, Y. Shi, D. Pinkel, T. Gray, A. Bradley, and H. E. Varmus. 1995. Deficiency of p53 accelerates mammary tumorigenesis in wnt-1 transgenic mice and promotes chromosomal instability. *Genes Devel*. 9:882-895.
5. Futreal, P. A., Q. Liu, D. Shattuck-Eidens, C. Cochran, K. Harshman, S. Tavtigian, L. Bennett, A. Haugenstrano, J. Swensen, Y. Miki, K. Eddington, M. McClure, C. Frye, J. Weaverfeldhaus, W. Ding, Z. Gholami, P. Soderkvist, L. Terry, S. Jhanwar, A. Berchuck, J. Iglehart, J. Marks, D. G. Ballinger, J. C. Barrett, M. H. Skolnick, and e. al. 1994. BRCA1 mutations in primary breast and ovarian carcinomas. *Science*. 266:120-122.
6. Gowen, L. C., B. L. Johnson, A. M. Latour, K. K. Sulik, and B. H. Koller. 1996. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. *Nat Genet*. 12:191-194.
7. Hakem, R., J. L. de la Pompa, A. Elia, J. Potter, and T. W. Mak. 1997. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. *Nat Genet*. 16:298-302.
8. Hakem, R., J. L. de la Pompa, C. Sirard, R. Mo, M. Woo, A. Hakem, A. P. Wakeham, J., A. Reitmair, F. Billia, E. Firpo, C. C. Hui, J. Roberts, J. Rossant, and T. W. Mak. 1996. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. *Cell*. 85:1009-1023.
9. Jin, Y., X. L. Xu, M. C. W. Yang, F. Wei, T. C. Ayi, A. M. Bowcock, and R. Baer. 1997. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. *Proc Natl Acad Sci U S A*. 94:12075-12080.
10. Lane, T. F., C. Deng, A. Elson, M. S. Lyu, C. A. Kozak, and P. Leder. 1995. Expression of Brca1 is Associated with Terminal Differentiation of Ectodermally- and Mesodermally-derived Tissues in Mice. *Genes Devel*. 9:2712-2722.
11. Liu, C. Y., A. Flesken-Nikitin, S. Li, Y. Zeng, and W. H. Lee. 1996. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. *Genes Dev*. 10:1835-1843.
12. Ludwig, T., D. Chapman, V. Papaioannou, and A. Efstratiadis. 1997. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. *Genes Dev*. 11:1226-1241.
13. Miki, Y., J. Swensen, D. Shattuck-Eidens, P. Futreal, K. Harshman, S. Tavtigian, Q. Y. Liu, C. Cochran, L. M. Bennett, W. Ding, R. Bell, J. Rosenthal, C. Hussey, T. Tran, M. McClure, C. Frye, T. Hattier, R. Phelps, A. Haugenstrano, H. Katcher, K. Yakumo, Z.

- Gholami, D. Shaffer, S. Stone, S. Bayer, and M. H. Skolnick. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*. 266:66-71.
14. Muller, W. J., E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. *Cell*. 54:105-115.
 15. Scully, R., J. Chen, R. L. Ochs, K. Keegan, M. Hoekstra, J. Feunteun, and D. M. Livingston. 1997. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. *Cell*. 90:425-435.
 16. Scully, R., J. Chen, A. Plug, Y. Xiao, D. Weaver, J. Feunteun, T. Ashley, and D. Livingston. 1997. Association of BRCA1 with Rad51 in mitotic and meiotic cells. *Cell*. 88:265-275.
 17. Thomas, J. E., M. Smith, B. Rubinfel, M. Gutowski, R. P. Beckmann, and P. Polakis. 1996. Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1. *Biol Chem*. 271:28630-28635.
 18. Thompson, M. E., R. A. Jensen, P. S. Obermiller, D. L. Page, and J. T. Holt. 1995. Decreased expression of *BRCA1* accelerates growth and is often present during sporadic breast cancer progression. *Nature Genetics*. 9:444-450.
 19. Wang, H., N. Shao, Q. M. Ding, J. Cui, E. S. Reddy, and V. N. Rao. 1997. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. *Oncogene*. 15:143-157.
 20. Wilson, C. A., M. N. Payton, G. S. Elliott, F. W. Buaas, E. E. Cajulis, D. Grosshans, L. Ramos, D. M. Reese, D. J. Slamon, and F. J. Calzone. 1997. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. *Oncogene*. 9:1-16.